Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; 2 Центральная клиническая больница «РЖД-Медицина», Москва, Россия docpolyakova.olga@gmail.com
Список исп. литературыСкрыть список 1. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res 2020; 127 (1): 4–20. DOI: 10.1161/CIRCRESAHA.120.316340 2. Di Carlo A, Bellino L, Consoli D et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 2019; 21 (10): 1468–1475. DOI:10.1093/europace/euz141 3. Staerk L, Wang B, Preis SR et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 2018; 361:k1453. DOI:10.1136/bmj.k1453 4. Svennberg E, Engdahl J, Al-Khalili F et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation 2015; 131 (25): 2176–2184. DOI: 10.1161/CIRCULATIONAHA.114. 014343 5. Vanassche T, Lauw MN, Eikelboom JW et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36 (5): 281–7a. DOI:10.1093/eurheartj/ehu307 6. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (5): 373–498. DOI:10.1093/eurheartj/ehaa612 7. Sposato LA, Cipriano LE, Saposnik G et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015; 14 (4): 377–387. DOI:10.1016/S1474-4422(15)70027-X 8. Piccini JP, Hammill BG, Sinner MF et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J 2014; 35 (4): 250–6. DOI:10.1093/eurheartj/eht483 9. Cintra FD, Figueiredo MJO. Atrial Fibrillation (Part 1): Pathophysiology, Risk Factors, and Therapeutic Basis. Arq Bras Cardiol 2021; 116 (1): 129–39. DOI:10.36660/abc.20200485 10. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91 (1): 265–325. DOI: 10.1152/physrev.00031.2009 11. Christophersen IE, Rienstra M, Roselli C et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet 2017; 49 (6): 946–52. DOI:10.1038/ng.3843 12. Chou CC, Chen PS. New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol Clin 2009; 27 (1): 35-viii. DOI:10.1016/j.ccl.2008.09.003 13. Akoum N, Daccarett M, McGann C et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol 2011; 22 (1): 16-22. DOI:10.1111/j.1540-8167.2010.01876.x 14. Chang TY, Chao TF, Liu CJ et al. The association between influenza infection, vaccination, and atrial fibrillation: A nationwide case-control study. Heart Rhythm 2016; 13 (6): 1189–94. DOI:10.1016/j.hrthm.2016.01.026 15. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50 (21): 2021–8. DOI:10.1016/j.jacc.2007.06.054 16. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104 (24): 2886–91. DOI:10.1161/hc4901.101760 17. Тревожно-фобические расстройства. Клинические рекомендации, утвержденные Минздравом России. М., 2021. URL: https://cr.minzdrav.gov.ru/recomend/455_2 Anxiety-phobic disorders. Clinical recommendations approved by the Ministry of Health of Russia. Moscow, 2021. URL: https://cr.minzdrav.gov.ru/recomend/455_2 (in Russian). 18. Полуэктов М.Г., Бузунов Р.В., Авербух В.М. и др. Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых. Consilium Medicum. Неврология и Ревматология. 2016; 2: 41–51. Poluektov M.G., Buzunov R.V., Averbukh VM et al. Project of clinical recommendations on diagnosis and treatment of chronic insomnia in adults. Consilium Medicum. Neurology and Rheumatology. 2016; 2: 41–51 (in Russian). 19. Bizhanov KA, Аbzaliyev KB, Baimbetov AK et al. Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review). J Cardiovasc Electrophysiol 2023; 34 (1): 153–65. DOI:10.1111/jce.15759 20. Dong XJ, Wang BB, Hou FF et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2019. Europace 2023; 25 (3): 793–803. DOI:10.1093/europace/euac237 21. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (7): 190–260. DOI: 10.15829/1560-4071-2021-4594 Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology 2021; 26 (7): 190–260 (in Russian). 22. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25 (3): 149–218. DOI:10.15829/1560-4071-2020-3-3786 Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149-218 DOI:10.15829/1560-4071-2020-3-3786 (in Russian). 23. Лекарственно-индуцированные заболевания. Том II: монография. Под общ. ред. Д.А. Сычева, О.Д. Остроумовой; ред. разделов А.И. Кочетков. М.: Прометей, 2022. ISBN 978-5-00172-304-2 [Drug-induced diseases. Volume II: monograph. Ed. by D.A. Sychev, O.D. Ostroumova; sections ed. by A.I. Kochetkov. Moscow: Prometheus, 2022. (in Russian)]. 24. Алгоритмы ведения пациентов с нарушениями ритма сердца: учеб. пособие. 2-е изд., испр. и доп. Под ред. Д.С. Лебедева, Е.Н. Михайлова. М.: Российское кардиологическое общество, 2021. ISBN 978_5_6044101_2_7 Algorithms of management of patients with cardiac rhythm disturbances: textbook. Ed. by D.S. Lebedev, E.N. Mikhailov. Moscow: Russian Cardiological Society, 2021. (in Russian). 25. Yao X, Abraham NS, Alexander GC et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc 2016; 5 (2): e003074. DOI:10.1161/JAHA.115.003074 26. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016; 72 (3): 329–38. DOI: 10.1007/s00228-015-1983-z 27. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm 2016; 22 (11): 1319–29. DOI:10.18553/jmcp.2016.22.11.1319 28. Lau WCY, Torre CO, Man KKC et al. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study. Ann Intern Med 2022; 175 (11): 1515–24. DOI: 10.7326/M22-0511 29. Grymonprez M, Steurbaut S, De Backer TL et al. Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol 2020; 11: 583311. DOI: 10.3389/fphar.2020.583311 30. Chao TF, Chiang CE, Liao JN t al. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chest 2020; 157 (5): 1266–1277. DOI: 10.1016/j.chest.2019.11.025 31. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28): 1864–1872. DOI: 10.1093/eurheartj/ehu046 32. Grymonprez M, Steurbaut S, De Backer TL et al. Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol 2020; 11: 583311. DOI: 10.3389/fphar.2020.583311 33. Pokorney SD, Chertow GM, Al-Khalidi HR et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation 2022; 146 (23): 1735–45. DOI: 10.1161/CIRCULATIONAHA.121.054990 34. Chang M, Yu Z, Shenker A et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016; 56 (5): 637–45. DOI: 10.1002/jcph.633 35. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11): 981–92. DOI: 10.1056/NEJMoa1107039 36. Hijazi Z, Hohnloser SH, Andersson U et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016; 1 (4): 451–60. DOI: 10.1001/jamacardio.2016.1170 37. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11): 981–92. DOI: 10.1056/NEJMoa1107039 38. Loffredo L, Perri L, Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. Dig Liver Dis 2015; 47 (5): 429–31. DOI: 10.1016/j.dld.2015.01.159 39. Miller CS, Dorreen A, Martel M et al. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (11): 1674–83.e3. DOI: 10.1016/j.cgh.2017.04.031